{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:54:42Z","timestamp":1740135282692,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eosinophilic peritonitis is a well-known complication at the initiation of peritoneal dialysis. It is often due to an allergic reaction to peritoneal dialysis solution or sometimes to the peritoneal dialysis catheter itself. Most cases are self-limiting with expected spontaneous resolution within a few weeks. Treatment is necessary for severe or persistent cases. However, the optimal treatment has not yet been defined. There have been only a few case reports on the use of anti-histamines and\/or steroids for the treatment of eosinophilic peritonitis. We reported a case of severe eosinophilic peritonitis successfully treated by switching the brand of peritoneal dialysis fluid (same glucose concentration). To the best of our knowledge, this is the first reported case employing such a treatment strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An eighty-two-year-old man with end-stage renal failure was started on continuous ambulatory peritoneal dialysis with Dianeal\u00ae (Baxter) peritoneal dialysis solution. He developed eosinophilic peritonitis 19 days after initiation of peritoneal dialysis. Infectious causes were ruled out by bacterial, fungal and tuberculosis smears and cultures. In view of the persistent and severe symptoms, we intervened by switching from Dianeal\u00ae (Baxter) peritoneal dialysis solution to Stay-Safe Balance\u00ae (Fresenius) solution with the same glucose concentration. His eosinophilic peritonitis resolved 5 days after switching the peritoneal dialysis solution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In severe or persistent cases of eosinophilic peritonitis requiring treatment, other than the use of steroids and anti-histamines, switching to a different brand of peritoneal dialysis solution can be considered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02786-8","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T08:02:41Z","timestamp":1650268961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resolution of severe eosinophilic peritonitis in a patient on continuous ambulatory peritoneal dialysis by changing from Dianeal peritoneal dialysis solution to Stay-Safe Balance solution: a case report"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-3388","authenticated-orcid":false,"given":"Zi","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Ho","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny Sze Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"2","key":"2786_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3904\/kjim.2004.19.2.121","volume":"19","author":"SY Oh","year":"2004","unstructured":"Oh SY, Kim H, Kang JM, et al. Eosinophilic peritonitis in a patient with continuous ambulatory peritoneal dialysis (CAPD). Korean J Intern Med. 2004;19(2):121\u20133.","journal-title":"Korean J Intern Med"},{"key":"2786_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0272-6386(88)80209-9","volume":"11","author":"MK Chan","year":"1988","unstructured":"Chan MK, Chow L, Lam SS, et al. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study. Am J Kidney Dis. 1988;11:180\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2786_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0896860820915019","volume":"40","author":"S Minato","year":"2020","unstructured":"Minato S, Miyazawa H, Kitano T, et al. Eosinophilic peritonitis induced by sucroferric oxyhydroxide. Perit Dial Int. 2020;40(4):419\u201321.","journal-title":"Perit Dial Int"},{"issue":"6","key":"2786_CR4","doi-asserted-by":"publisher","first-page":"030006052110253","DOI":"10.1177\/03000605211025367","volume":"49","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li Z, Luo S, et al. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review. J Int Med Res. 2021;49(6):030006052110253.","journal-title":"J Int Med Res."},{"issue":"2","key":"2786_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000431085","volume":"5","author":"Y Xu","year":"2015","unstructured":"Xu Y, Gao C, Xu J, Chen N. Successful Treatment of Idiopathic Eosinophilic Peritonitis by Oral Corticosteroid Therapy in a Continuous Ambulatory Peritoneal Dialysis Patient. Case Rep Nephrol Dial. 2015;5(2):130\u20134.","journal-title":"Case Rep Nephrol Dial"},{"issue":"3","key":"2786_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3747\/pdi.2010.00058","volume":"31","author":"AS Albilali","year":"2011","unstructured":"Albilali AS, Rahim KA, Edrees BM, Alshaya HO. Resolution of eosinophilic peritonitis with oral prednisolone in a child receiving peritoneal dialysis. Perit Dial Int. 2011;31(3):359\u201360.","journal-title":"Perit Dial Int"},{"issue":"4","key":"2786_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/089686089701700419","volume":"17","author":"SS Thakur","year":"1997","unstructured":"Thakur SS, Unikowsky B, Prichard S. Eosinophilic peritonitis in CAPD: treatment with prednisone and diphenhydramine. Perit Dial Int. 1997;17(4):402\u20133.","journal-title":"Perit Dial Int"},{"issue":"3","key":"2786_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0272-6386(97)90290-0","volume":"30","author":"S Tang","year":"1997","unstructured":"Tang S, Lo CY, Lo WK, Chan TM. Resolution of eosinophilic peritonitis with ketotifen. Am J Kidney Dis. 1997;30(3):433\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2786_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00467-013-2718-y","volume":"29","author":"TA Forbes","year":"2014","unstructured":"Forbes TA, Lunn AJ. Montelukast: a novel therapeutic option in eosinophilic peritonitis. Pediatr Nephrol. 2014;29(7):1279\u201382.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"2786_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00467-017-3847-5","volume":"33","author":"S Tzvi-behr","year":"2018","unstructured":"Tzvi-behr S, Frishberg Y, Ben-shalom E, Rinat C, Becker-cohen R. Eosinophilia in a peritoneal dialysis patient: Answers. Pediatr Nephrol. 2018;33(9):1507\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2786_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/ajkd.2002.36341","volume":"40","author":"R MacGinley","year":"2002","unstructured":"MacGinley R, Cooney K, Alexander G, Cohen S, Goldsmith DJA. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. American J Kidney Dis. 2002;40(5):1030\u20135.","journal-title":"American J Kidney Dis"},{"issue":"9459","key":"2786_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0140-6736(05)70800-X","volume":"365","author":"L Martis","year":"2005","unstructured":"Martis L, Patel M, Giertych J, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet. 2005;365(9459):588\u201394.","journal-title":"Lancet"},{"issue":"5","key":"2786_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3747\/pdi.2011.00169","volume":"32","author":"DW Johnson","year":"2012","unstructured":"Johnson DW, Brown FG, Clarke M, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int. 2012;32(5):497\u2013506.","journal-title":"Perit Dial Int"},{"key":"2786_CR14","doi-asserted-by":"crossref","unstructured":"Cho Y, Johnson DW, Craig JC, Strippoli GFM, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews. 2014;(Issue 3):CD007554.","DOI":"10.1002\/14651858.CD007554.pub2"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02786-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T11:10:25Z","timestamp":1650366625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02786-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2786"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02786-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"United Christian Hospital does not require ethical approval for reporting individual cases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient(s) for their anonymised information to be published in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}